(News Bulletin 247) – Poxel rose on the stock market on Tuesday following the publication in the medical journal ‘Journal of Hepatology’ of the positive results of its phase II study in the treatment of NASH.
As a reminder, this clinical trial on PXL065 had reached its primary efficacy endpoint relating to the reduction in the level of fatty mass in the liver after 36 weeks of treatment for all doses.
Improvement in fibrosis of at least one stage without worsening of NASH, one of the criteria for FDA approval, was observed in 31-50% of patients who received PXL065 compared to 17% in the placebo group .
Dr. Stephen Harrison, the lead author of the paper and principal investigator of the study, believes that this publication in such a prestigious journal is an ‘important step’ in the development of new treatments for NASH.
‘With PXL065, a promising and differentiated clinical profile, combining a reduction in the rate of fat mass in the liver, improvements in fibrosis and metabolic benefits, and presenting very good safety and harmlessness, is emerging’, emphasizes the doctor.
“PXL065 deserves further study in a pivotal study that could lead to a major new oral drug in the treatment of NASH, with the added possibility of using it in combination with other therapies,” adds he.
Following these announcements, the Poxel title climbed almost 33% on Tuesday on the Paris Stock Exchange.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
